Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0431A XR in pediatric type 2 diabetes inadequately controlled on metformin
2012-004035-23Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoint: A1C. Started Dec 2012; status: completed.
02
Drugs
sitagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-004035-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004035-23.